| Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults B Killingley, AJ Mann, M Kalinova, A Boyers, N Goonawardane, J Zhou, ... Nature Medicine 28 (5), 1031-1041, 2022 | 409 | 2022 |
| Viral load drives disease in humans experimentally infected with respiratory syncytial virus JP DeVincenzo, T Wilkinson, A Vaishnaw, J Cehelsky, R Meyers, ... American journal of respiratory and critical care medicine 182 (10), 1305-1314, 2010 | 370 | 2010 |
| Animal models in influenza vaccine testing JW Van Der Laan, C Herberts, R Lambkin-Williams, A Boyers, AJ Mann, ... Expert review of vaccines 7 (6), 783-793, 2008 | 108 | 2008 |
| A plant‐produced influenza subunit vaccine protects ferrets against virus challenge V Mett, K Musiychuk, H Bi, CE Farrance, A Horsey, N Ugulava, Y Shoji, ... Influenza and other respiratory viruses 2 (1), 33-40, 2008 | 98 | 2008 |
| Preclinical evaluation of a replication-deficient intranasal ΔNS1 H5N1 influenza vaccine J Romanova, BM Krenn, M Wolschek, B Ferko, ... PloS one 4 (6), e5984, 2009 | 93 | 2009 |
| Vaccine efficacy in adults in a respiratory syncytial virus challenge study B Schmoele-Thoma, AM Zareba, Q Jiang, MS Maddur, R Danaf, A Mann, ... New England Journal of Medicine 386 (25), 2377-2386, 2022 | 84 | 2022 |
| Comparing influenza and RSV viral and disease dynamics in experimentally infected adults predicts clinical effectiveness of RSV antivirals B Bagga, CW Woods, TH Veldman, A Gilbert, A Mann, G Balaratnam, ... Antiviral therapy 18 (6), 785-792, 2013 | 70 | 2013 |
| A synthetic influenza virus vaccine induces a cellular immune response that correlates with reduction in symptomatology and virus shedding in a randomized phase Ib live-virus … O Pleguezuelos, S Robinson, A Fernández, GA Stoloff, A Mann, A Gilbert, ... Clinical and Vaccine Immunology 22 (7), 828-835, 2015 | 69 | 2015 |
| Treatment of epidemic and pandemic influenza with neuraminidase and M2 proton channel inhibitors JS Oxford, S Bossuyt, S Balasingam, A Mann, P Novelli, R Lambkin Clinical microbiology and infection 9 (1), 1-14, 2003 | 55 | 2003 |
| Strong local and systemic protective immunity induced in the ferret model by an intranasal virosome-formulated influenza subunit vaccine R Lambkin, JS Oxford, S Bossuyt, A Mann, IC Metcalfe, C Herzog, JF Viret, ... Vaccine 22 (31-32), 4390-4396, 2004 | 51 | 2004 |
| The human viral challenge model: accelerating the evaluation of respiratory antivirals, vaccines and novel diagnostics R Lambkin-Williams, N Noulin, A Mann, A Catchpole, AS Gilbert Respiratory research 19, 1-15, 2018 | 49 | 2018 |
| Interfering vaccine (defective interfering influenza A virus) protects ferrets from influenza, and allows them to develop solid immunity to reinfection A Mann, AC Marriott, S Balasingam, R Lambkin, JS Oxford, NJ Dimmock Vaccine 24 (20), 4290-4296, 2006 | 49 | 2006 |
| A new intranasal influenza vaccine based on a novel polycationic lipid-ceramide carbamoyl-spermine (CCS). II. Studies in mice and ferrets and mechanism of adjuvanticity O Even-Or, A Joseph, N Itskovitz-Cooper, S Samira, E Rochlin, H Eliyahu, ... Vaccine 29 (13), 2474-2486, 2011 | 48 | 2011 |
| Viral emissions into the air and environment after SARS-CoV-2 human challenge: a phase 1, open label, first-in-human study J Zhou, A Singanayagam, N Goonawardane, M Moshe, FP Sweeney, ... The Lancet Microbe 4 (8), e579-e590, 2023 | 42 | 2023 |
| Immunogenicity, protective efficacy and mechanism of novel CCS adjuvanted influenza vaccine O Even-Or, S Samira, E Rochlin, S Balasingam, AJ Mann, ... Vaccine 28 (39), 6527-6541, 2010 | 40 | 2010 |
| Differential evolution of peripheral cytokine levels in symptomatic and asymptomatic responses to experimental influenza virus challenge MT McClain, R Henao, J Williams, B Nicholson, T Veldman, L Hudson, ... Clinical & Experimental Immunology 183 (3), 441-451, 2016 | 39 | 2016 |
| Anti-viral Formulations Nanomaterials And Nanoparticles G Ren, JS Oxford, PW Reip, R Lambkin-Williams, A Mann US Patent App. 12/279,627, 2010 | 39 | 2010 |
| Correlation between human leukocyte antigen class II alleles and HAI titers detected post-influenza vaccination AJ Moss, FP Gaughran, A Karasu, AS Gilbert, AJ Mann, CM Gelder, ... PloS one 8 (8), e71376, 2013 | 37 | 2013 |
| The effect of influenza virus on the human oropharyngeal microbiome E Ramos-Sevillano, WG Wade, A Mann, A Gilbert, R Lambkin-Williams, ... Clinical Infectious Diseases 68 (12), 1993-2002, 2019 | 36 | 2019 |
| Intranasal H5N1 vaccines, adjuvanted with chitosan derivatives, protect ferrets against highly pathogenic influenza intranasal and intratracheal challenge AJ Mann, N Noulin, A Catchpole, KJ Stittelaar, L De Waal, ... PloS one 9 (5), e93761, 2014 | 36 | 2014 |
